702 related articles for article (PubMed ID: 17320799)
21. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
[TBL] [Abstract][Full Text] [Related]
22. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
[TBL] [Abstract][Full Text] [Related]
23. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
24. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
25. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
26. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
28. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
29. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
30. New insights into molecular mechanisms of diffuse coronary ectasiae: a possible role for VEGF.
Savino M; Parisi Q; Biondi-Zoccai GG; Pristipino C; Cianflone D; Crea F
Int J Cardiol; 2006 Jan; 106(3):307-12. PubMed ID: 16337037
[TBL] [Abstract][Full Text] [Related]
31. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls.
Stojanovic N; Lewandowski K; Salata I; Bienkiewicz M; Tuck S; Prelevic G; Press M
Gynecol Endocrinol; 2010 Mar; 26(3):201-7. PubMed ID: 19526397
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
34. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome.
Liu PY; Li YH; Chan SH; Lin LJ; Wu HL; Shi GY; Chen JH
Am J Cardiol; 2006 Oct; 98(8):1012-7. PubMed ID: 17027562
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
36. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients.
Ozkök E; Aydin M; Babalik E; Ozbek Z; Ince N; Kara I
Med Sci Monit; 2008 Oct; 14(10):CR536-42. PubMed ID: 18830194
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
Bjerkeli V; Halvorsen B; Damås JK; Nordøy I; Yndestad A; Aukrust P; Frøland SS
Ann Rheum Dis; 2004 Dec; 63(12):1659-63. PubMed ID: 15547092
[TBL] [Abstract][Full Text] [Related]
38. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
39. A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury.
Jacob-Ferreira AL; Passos CJ; Gerlach RF; Barbosa F; Tanus-Santos JE
Sci Total Environ; 2010 Sep; 408(19):4085-92. PubMed ID: 20554312
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients.
Chen QJ; Lu L; Peng WH; Hu J; Yan XX; Wang LJ; Zhang Q; Zhang RY; Shen WF
Clin Chim Acta; 2009 Jul; 405(1-2):97-103. PubMed ID: 19376102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
